Synthesis and evaluation of dopamine D-3 receptor antagonist C-11-GR218231 as PET tracer for P-glycoprotein by de Vries, Eruk F. J. et al.
  
 University of Groningen
Synthesis and evaluation of dopamine D-3 receptor antagonist C-11-GR218231 as PET
tracer for P-glycoprotein
de Vries, Eruk F. J.; Kortekaas, Rudie; van Waarde, Aaren; Dijkstra, Durk; Elsinga, Philip H.;
Vaalburg, W.
Published in:
Journal of Nuclear Medicine
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2005
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
de Vries, E. F. J., Kortekaas, R., van Waarde, A., Dijkstra, D., Elsinga, P. H., & Vaalburg, W. (2005).
Synthesis and evaluation of dopamine D-3 receptor antagonist C-11-GR218231 as PET tracer for P-
glycoprotein. Journal of Nuclear Medicine, 46(8), 1384-1392.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
Synthesis and Evaluation of Dopamine D3
Receptor Antagonist 11C-GR218231 as PET
Tracer for P-Glycoprotein
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Philip H. Elsinga, PhD1; and Willem Vaalburg, PhD1
1PET Center, University Medical Center Groningen, Groningen, The Netherlands; 2Department of Neurology, University Medical
Center Groningen, Groningen, The Netherlands; 3Department of Anatomy, University of Groningen, Groningen, The Netherlands;
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While searching for a PET method to determine the density and
occupancy of the dopamine D3 receptor, we found evidence
that suggested that the dopamine D3 antagonist GR218231
could be a substrate of the P-glycoprotein efflux pump. P-
glycoprotein protects the brain against toxic substances and
xenobiotics, but it also hampers the delivery of various drugs
into the brain. In this study, we aimed to explore whether radio-
labeled GR218231 could be applied as a PET tracer for moni-
toring P-glycoprotein activity in the blood–brain barrier. Such an
imaging technique could be useful for the development of new
drugs and novel strategies to deliver drugs to the brain and for
identification of undesirable drug–drug interactions. Methods:
As a potential PET tracer, GR218231 was labeled with 11C by
reaction of the newly synthesized desmethyl precursor with
11C-methyl triflate. The biodistribution of 11C-GR218231 was
determined in rats. To assess specific binding to the dopamine
D3 receptor, blocking experiments with unlabeled GR218231
(0.2 and 2.5 mg/kg) were performed. To demonstrate the influ-
ence of P-glycoprotein on cerebral uptake of 11C-GR218231,
the efflux pump was modulated with 50 mg/kg cyclosporine A.
The sensitivity of 11C-GR218231 for P-glycoprotein modulation
was assessed in dose–response studies, using escalating cy-
closporine A dosages. Results: 11C-GR218231 was prepared in
53%  8% decay-corrected radiochemical yield and had a
specific activity of 15  10 GBq/mol (mean  SD). Biodistri-
bution studies in rats revealed a low and homogeneous uptake
in the brain. Pretreatment of the animals with unlabeled
GR218231 did not demonstrate any specific binding. Modula-
tion of P-glycoprotein with cyclosporine A caused a 12-fold
higher 11C-GR218231 uptake in the brain, indicating that the low
cerebral tracer uptake was caused by the P-glycoprotein efflux
pump in the blood–brain barrier. Cyclosporine A dose-escala-
tion studies showed a dose-dependent sigmoidal increase in
11C-GR218231 uptake in brain and spleen (median effective
dose [ED50], 23.3  0.6 and 38.4  2.4 mg/kg, respectively),
whereas a dose-dependent decrease was observed in the pan-
creas (ED50, 36.0  4.4 mg/kg). Conclusion: Although 11C-
GR218231 is unsuited for dopamine D3 receptor imaging with
PET, it appears to be an attractive PET tracer for visualization
and quantification of P-glycoprotein activity in the blood–brain
barrier.
Key Words: PET; dopamine D3 receptor; GR218231; P-glyco-
protein; blood–brain barrier
J Nucl Med 2005; 46:1384–1392
The blood–brain barrier protects the brain from harmful
substances and xenobiotics from the environment (1). The
access of large and polar molecules to the brain is restricted
by the brain microvasculature, which lacks fenestrations
and has close tight junctions with a high electrical resis-
tance. Consequently, passive diffusion across the brain en-
dothelium is only possible for small lipophilic molecules,
typically with an octanol–water partition coefficient (logP)
between 0.9 and 2.5 (2). Efflux pumps, such as the ABC
transporters P-glycoprotein and multidrug resistance–asso-
ciated protein, also contribute to the blood–brain barrier by
extruding a variety of small lipophilic substances from the
brain endothelium back into the circulation. The integrity of
the blood–brain barrier is of crucial importance for the
brain, because failure of the blood–brain barrier leads to
exposure of the brain to toxic agents that can cause degen-
eration of brain tissue.
Since the blood–brain barrier prevents the accumulation
of potentially harmful compounds in the brain, it can also be
a major obstacle for the delivery of drugs to the brain.
P-glycoprotein is an adenosine triphosphate–driven efflux
pump that has a major contribution to the blood–brain
barrier. Many structurally unrelated drugs, including vari-
ous anticancer drugs, antidepressants, steroids, and HIV
protease inhibitors, are substrates of P-glycoprotein and are
extruded from the brain by the efflux pump (3). Conse-
quently, drug levels in the brain remain below therapeutic
levels, resulting in poor therapy findings. Coadministration
of another P-glycoprotein substrate (modulator), such as
cyclosporine A, can induce an increase in the concentration
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of the therapeutic drug in the brain, due to competition
between both substrates for the efflux pump (4). Thus,
modulation of P-glycoprotein could be applied to improve
the efficacy of chemotherapeutic treatment. However, unin-
tentional modulation of P-glycoprotein that can occur when
multiple drugs are combined can also lead to an unexpected
increase in drug levels in the brain, which might cause
neurotoxic side effects.
Nuclear imaging techniques, such as PET, enable the
measurement of the tissue concentrations of radiolabeled
P-glycoprotein substrates as a function of time. Such an
imaging technique allows noninvasive monitoring of P-
glycoprotein activity in the blood–brain barrier and there-
fore could be an attractive tool for the development of novel
strategies to improve the delivery of drugs into the brain.
For example, PET could be applied to evaluate the efficacy
of novel P-glycoprotein modulators and to optimize the
dosing schedule. Another interesting application could be
monitoring of P-glycoprotein functionality in psychiatric
and neurologic disorders, which could implicate the efflux
pump as a possible cause in these diseases (5). Currently,
several radiolabeled drugs, including 11C-verapamil and
11C-carvedilol, are under investigation as PET tracers for
P-glycoprotein (3). Applications of these tracers in human
modulation studies, however, is hampered by the lack of
potent P-glycoprotein modulators that can be administered
safely to humans at the dosage that is required for sufficient
modulation to achieve maximum tracer uptake. The aim of
this study was to evaluate 11C-GR218231 (Fig. 1) as a novel
PET tracer for measuring P-glycoprotein activity.
GR218231 is an antagonist of the dopamine D3 receptor,
which was selected as a potential radiotracer for measuring
the density and occupation of the dopamine D3 receptor in
the brain with PET. In vitro, GR218231 exhibits a high
affinity and selectivity for the dopamine D3 receptor (6,7).
The (R)-isomer of GR218231 (pKi  8.9) is slightly more
potent than the racemic mixture (pKi  8.8) and the com-
pound is sufficiently lipophilic for penetration of the blood–
brain barrier (logD  2.2) (7). In vivo, GR218231 behaves
as an antagonist at the dopamine D3 receptor but is inactive
in animal models for D2 receptor–mediated effects, such as
models for antipsychotic and extrapyramidal activity (6,8).
The course of the evaluation studies of radiolabeled
GR218231 as a PET tracer for the dopamine D3 receptor,
however, led us to believe that this compound is a substrate
of the P-glycoprotein pump. Previously, other dopamine
receptor agonists and antagonists, such as domperidone (9),
bromocriptine (10), and flupentixol (11), have also been
identified as substrates of the P-glycoprotein pump. The
efflux pump can reduce brain uptake of radiotracers and,
thus, hampers successful imaging by decreasing the signal-
to-noise ratio (12,13). This prompted us to investigate a new
and interesting application of radiolabeled GR218231: as
PET tracer for imaging of P-glycoprotein activity.
This article describes the radiolabeling of racemic dopa-
mine D3 receptor antagonist GR218231 with the positron
emitter 11C and the investigation of its normal brain uptake
and biodistribution in rats. In addition, the effect of modu-
lation of the P-glycoprotein efflux pump on uptake of 11C-
GR218231 in the brain is described.
MATERIALS AND METHODS
Materials
Solvents and reagents were obtained from commercial suppliers
and used without further purification. 1H NMR (200 MHz) and 13C
NMR (50 MHz) spectra were recorded on a Varian Gemini 200
spectrometer. 1H and 13C chemical shifts were determined relative
to the signal of the solvent, converted to the tetramethylsilane
(TMS) scale and expressed in -units (ppm) downfield from TMS.
Melting points were measured with a Mettler FP61 apparatus.
High-performance liquid chromatographic (HPLC) analyses and
preparative separations were performed on a Waters system, con-
sisting of a 515 isocratic pump, a 486 multiwavelength ultraviolet
detector operated at 254 nm, and a Bicron Geiger–Mu¨ller radio-
activity detector.
Chemistry
6-Bromo-2-(N,N-Di-n-Propylamino)Tetralin (Compound 2). To
a solution of 5.0 g (22 mmol) 6-bromo-2-tetralone (compound 1)
in 200 mL methanol on 4-Å molecular sieves, 15 mL (111 mmol,
5 eq) di-n-propylamine were added. The reaction mixture was
stirred at room temperature for 1 h, after which 7.0 g (111 mmol,
5 eq) NaBH3CN were slowly added. The pH of the reaction
mixture was adjusted to 6 by adding glacial acetic acid. After
stirring at room temperature for 72 h, the reaction mixture was
filtered. The filtrate was concentrated in vacuo. The residue was
dissolved in a mixture of 200 mL 1N HCl, 100 mL water, and 150
mL ethyl acetate. The layers were separated and the water layer
was washed with 150 mL ethyl acetate. The combined organic
layers were extracted 5 times with 75 mL 1N HCl and subse-
quently discarded. All aqueous layers were combined and solid
NaOH was added until the pH was 10. The basic water layer was
extracted 3 times with 150 mL ethyl acetate. The combined or-
ganic layers were dried on MgSO4 and concentrated in vacuo,
affording 2.6 g (38%) of compound 2 as yellow oil. 1H NMR (200
MHz, CDCl3):  7.22 (s, 1H, Ar), 7.19 (d, 1H, J  9.0 Hz, Ar),
6.94 (d, 1H, J  9.0 Hz, Ar), 3.00–2.65 (m, 5H, CH2CHN), 2.47
FIGURE 1. Synthesis of GR218231 and its labeling precursor,
Compound 6, using the following reagents and conditions: (A)
(CH3CH2CH2)2NH, NaCNBH3, MeOH; (B) (i) n-BuLi, tetrahydro-
furan, 78°C; (ii) N,N-dimethylformamide; (iii) NaBH4, MeOH;
(C) (i) SOCl2, CHCl3; (ii) ROC6H4SH, K2CO3, Kryptofix 2.2.2.,
CHCl3; (D) (i) HCl, EtOH; (ii) m-chloroperbenzoic acid, CH2Cl2.
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(t, 4H, J  7.6 Hz, CH2N), 2.06–1.97 (m, 1H, CH2), 1.69–1.38
(m, 5H, CH2), 0.88 (t, 6H, J  7.3 Hz, CH3).
2-(N,N-Di-n-Propylamino)-6-(Hydroxymethyl)Tetralin (Com-
pound 3). Under an argon atmosphere, 12.1 mL 1.6N (19.4 mmol,
2 eq) n-butyllithium in hexane were added to a solution of 3.0 g
(9.7 mmol) of compound 2 in 60 mL of freshly distilled (from
sodium/benzophenone) tetrahydrofuran (THF) at 80°C. After
stirring at 80°C for 15 min, 3.7 mL (48 mmol, 5 eq) anhydrous
N,N-dimethylformamide (DMF) were added. The reaction mixture
was allowed to warm to room temperature in 1 h, after which
stirring was continued for 1 h. The reaction was quenched by the
addition of 150 mL water and the reaction mixture was extracted
3 times with 100 mL ethyl acetate. The combined organic layers
were washed twice with 200 mL of water, dried on Na2SO4, and
concentrated in vacuo. The crude aldehyde (2.68 g) was dissolved
in 100 mL methanol. To this solution, 0.8 g (20 mmol, 2 eq)
NaBH4 was slowly added. The reaction mixture was stirred at
room temperature for 1 h and subsequently concentrated in vacuo
to a volume of approximately 50 mL. The residue was diluted with
250 mL water and extracted 3 times with 100 mL ethyl acetate.
The combined organic layers were washed with 200 mL water,
dried on MgSO4, and concentrated in vacuo. The crude product
was purified by flash column chromatography over a silica gel 60
column, using ethyl acetate/n-hexane/triethylamine (20:78:2) as
the eluent. This yielded 1.35 g (53%) of compound 3, as a white
solid. Melting point: 53°C. 1H NMR (200 MHz, CDCl3):  7.08 (s,
3H, Ar), 4.61 (s, 2H, CH2O), 3.04–2.65 (m, 5H, CH2CHN), 2.48
(t, 4H, J  7.6 Hz, CH2N), 2.07–1.98 (m, 1H, CH2), 1.79 (bs, 1H,
OH), 1.70–1.38 (m, 5H, CH2), 0.89 (t, 6H, J  7.8 Hz, CH3). 13C
NMR (50 MHz, CDCl3):  136.8, 135.2, 134.6, 128.2, 125.8,
123.0, 63.7, 55.4, 51.1, 30.4, 28.4, 24.4, 20.5, 10.4.
2-(N,N-Di-n-Propylamino)-6-(4-Hydroxyphenylthiomethyl)Te-
tralin (Compound 4). Thionyl chloride (340 L, 4.6 mmol, 4 eq)
was slowly added to a solution of 300 mg (1.16 mmol) of com-
pound 3 in 10 mL CHCl3. The reaction mixture was stirred at
ambient temperature for 2 h. The mixture was poured into 50 mL
water and extracted twice with 25 mL CHCl3. The combined
organic layers were washed with 50 mL 0.5 mol/L K2CO3, dried
on MgSO4, and concentrated in vacuo. To remove traces of SOCl2,
the residue was dissolved in 50 mL 1,2-dichloroethane and con-
centrated again. The crude chloride (0.53 g) was dissolved in 20
mL CHCl3. To this solution, 0.30 g (2.4 mmol, 2 eq) 4-mercap-
tophenol, 0.45 g (3.3 mmol, 2.8 eq) K2CO3, and 25 mg (66 mol,
0.06 eq) Kryptofix 2.2.2. (Merck) were subsequently added. After
the reaction mixture was stirred at room temperature for 18 h, 25
mL water were added. The layers were separated and the water
layer was extracted twice with 20 mL CHCl3. The combined
organic layers were washed twice with 25 mL water, dried on
Na2SO4, and concentrated in vacuo. The crude product was puri-
fied by flash column chromatography over a silica gel 60 column,
using ethyl acetate/n-hexane/triethylamine (40:58:2) as the eluent.
The desired product was obtained as colorless glassy oil in 71%
yield (300 mg). 1H NMR (200 MHz, CDCl3):  7.22 (d, 2H, J 
8.6 Hz, Ar), 6.99–6.89 (m, 3H, Ar), 6.72 (d, 2H, J  8.6 Hz, Ar),
3.92 (s, 2H, CH2S), 3.00–2.82 (m, 5H, CH2CHN), 2.50 (t, 4H,
J  7.7 Hz, CH2N), 2.0 (m, 1H, CH2), 1.65–1.40 (m, 5H, CH2),
0.88 (t, 6H, J  7.8 Hz, CH3).
2-(N,N-Di-n-Propylamino)-6-(4-Methoxyphenylthiomethyl)Te-
tralin (Compound 5). Compound 5 was prepared in the same
manner as was described for compound 4, using 4-mercaptoanisol
instead of 4-mercaptophenol. The crude product was purified by
flash column chromatography over a silica gel 60 column, using
ethyl acetate/n-hexane/triethylamine (10:88:2) as the eluent. For
further purification, the product was dissolved in 25 mL 1N HCl
and 25 mL diethyl ether. The layers were separated and the organic
layer was extracted twice with 25 mL 1N HCl. Solid NaOH was
added to the combined aqueous layers until the pH was 10. The
basic solution was extracted twice with 25 mL diethyl ether. The
organic layers were dried on MgSO4 and concentrated in vacuo,
affording 318 mg (72%) of compound 5 as a white solid. Melting
point: 46°C. 1H NMR (200 MHz, CDCl3):  7.28 (d, 2H, J  8.9
Hz, Ar), 7.01–6.92 (m, 3H, Ar), 6.81 (d, 2H, J  8.9 Hz, Ar), 3.94
(s, 2H, CH2S), 3.79 (s, 3H, CH3O), 2.97–2.69 (m, 5H,
CH2CHN), 2.47 (t, 4H, J  7.6 Hz, CH2N), 2.0 (m, 1H, CH2),
1.69–1.38 (m, 5H, CH2), 0.89 (t, 6H, J  7.5 Hz, CH3).
2-(N,N-Di-n-Propylamino)-6-(4-Hydroxyphenylsulfonylmethyl)-
Tetralin (Compound 6). To a solution of 300 mg (0.82 mmol) of
compound 4 in 50 mL absolute ethanol, 37% HCl was added drop
by drop until the pH was 1. The solvent was evaporated in vacuo
and the residue was dissolved in 10 mL CH2Cl2. To this solution,
0.47 g (1.8 mmol, 2 eq) 70%–75% m-chloroperoxybenzoic acid
was added and the reaction mixture was stirred overnight at room
temperature. The mixture was washed with 50 mL 0.5N NaHCO3.
The water layer was extracted twice with 20 mL CH2Cl2. The
combined organic layers were washed with 40 mL water, dried on
Na2SO4, and concentrated in vacuo. The crude product was puri-
fied by flash column chromatography over a silica gel 60 column,
using methanol/CH2Cl2/triethylamine (4:95:1) as the eluent. For
further purification, the product was dissolved in 50 mL 1N HCl
and 25 mL ethyl acetate. The layers were separated and the organic
layer was extracted twice with 25 mL 1N HCl. The combined
aqueous layers were neutralized first with solid NaOH to pH 4 and
then with NaHCO3 to pH 8. The solution was extracted twice with
25 mL diethyl ether. The organic layers were dried on Na2SO4 and
concentrated in vacuo, affording 140 mg (43%) of compound 6 as
a white solid. Melting point: 67°C. 1H NMR (200 MHz, CDCl3):
 7.41 (d, 2H, J  8.8 Hz, Ar), 6.95–6.75 (m, 5H, Ar), 4.18 (s, 2H,
CH2S), 3.07–2.56 (m, 9H, CH2CHN), 2.0 (m, 1H, CH2), 1.66–
1.51 (m, 5H, CH2), 0.91 (t, 6H, J  7.2 Hz, CH3). 13C NMR (50
MHz, CDCl3):  162.4, 134.6, 134.4, 129.5, 129.4, 128.0, 126.7,
125.1, 124.5, 114.9, 61.4, 56.0, 51.0, 29.7, 27.8, 23.7, 19.3, 10.3.
Combustion analysis: calculated for C23H31NO3S: C 68.8, H 7.8, N
3.5; found: C 66.6, H 7.9, N 3.8.
2-(N,N-Di-n-Propylamino)-6-(4-Methoxyphenylsulfonylmethyl)-
Tetralin (GR218231). GR218231 was prepared in the same man-
ner as was described for compound 6, using compound 5 as the
starting material. After the reaction was completed, the reaction
mixture was washed with 50 mL 1N NaOH. The water layer was
extracted twice with 25 mL CH2Cl2. The combined organic layers
were washed with 25 mL water, dried on MgSO4, and concentrated
in vacuo. The crude product was dissolved in 50 mL absolute
ethanol and acidified with 37% HCl until the pH was 1. The
solvent was evaporated in vacuo. The residue was taken up in 75
mL diethyl ether and stirred for 72 h. The white suspension was
filtered and washed with ether. The residue was further purified by
flash column chromatography over a silica gel 60 column, using
CH2Cl2/n-hexane/triethylamine (20:78:2) as the eluent. The prod-
uct was obtained as a white solid in 50% yield. Melting point:
97°C (free base). 	max (40% acetonitrile in 0.1N NaH2PO4): 243
nm. 1H NMR (200 MHz, CDCl3):  7.57 (d, 2H, J  9.0 Hz, Ar),
6.99–6.75 (m, 5H, Ar), 4.19 (s, 2H, CH2S), 3.87 (s, 3H, CH3O),
3.00–2.71 (m, 5H, CH2CHN), 2.47 (t, 4H, J  7.5 Hz, CH2N),
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2.0 (m, 1H, CH2), 1.62–1.38 (m, 5H, CH2), 0.88 (t, 6H, J 7.3 Hz,
CH3). 13C NMR (50 MHz, CDCl3):  162.2, 135.8, 135.3, 129.5,
129.3, 128.3, 128.1, 126.4, 123.9, 112.5, 61.3, 55.3, 54.1, 51.1,
30.4, 28.1, 24.1, 20.5, 10.4. Combustion analysis: calculated for
C24H33NO3S: C 69.4, H 8.0, N 3.4; found: C 69.1, H 7.9, N 3.4.
Radiochemistry
2-(N,N-Di-n-Propylamino)-6-(4-11C-Methoxyphenylsulfonyl-
methyl)Tetralin (11C-GR218231). 11C-Methane was produced by
the 14N(p,
)11C nuclear reaction, using a Scanditronix MC17 cy-
clotron to irradiate the N2  5% H2 target gas with 17-MeV
protons. 11C-Methyl iodide was prepared from 11C-methane (14)
and converted into 11C-methyl triflate (15) via procedures that have
been described previously in the literature. 11C-Methyl triflate was
transported by a stream of argon (20 mL/min) into a minivial
containing 0.5 mg precursor 6 and 2.5 L 0.5N NaOH dissolved
in 300 L methanol at room temperature. After the trapping of
11C-methyl triflate was complete, the solvent was evaporated at
80°C with the aid of an argon flow. The residue was dissolved in
1.5 mL 40% acetonitrile in 0.1 mol/L NaH2PO4 and injected into
a semipreparative reversed-phase HPLC column. Purification of
the product was accomplished, using an alphabond C18 column (10
m, 7.8  300 mm) with 40% acetonitrile in NaH2PO4 as the
eluent at 3 mL/min flow rate. The radioactive product with a
retention time of 12 min was collected (retention time of com-
pound 6, 7 min). The product was diluted with 15 mL water and
transferred to an Oasis SepPak cartridge (Waters). The cartridge
was washed with 5 mL water and eluted with 0.5 mL ethanol
followed by 4.5 mL 0.9% NaCl solution, affording the tracer
solution ready for injection in animal experiments. In this manner,
11C-GR218231 with a specific activity of 15  10 GBq/mol was
prepared in 53%  8% (n  18) decay-corrected radiochemical
yield (based on 11C-methyl triflate). The total synthesis time,
including the preparation of 11C-methyl triflate, HPLC purification,
and formulation, was approximately 40 min. The identity of the
product was confirmed by coinjection with a reference sample on
reversed-phase HPLC. The radiochemical purity of the product
was 99%, as determined by analytic reversed-phase HPLC using
a Platinum C18 column (5 m, 4.6  250 mm) and 60% MeOH in
0.1 mol/L NaH2PO4 as the eluent at a flow rate of 1 mL/min
(retention time, 11.5–12 min).
Biodistribution Studies
Male Wistar rats (236–330 g) were anesthetized by intraperi-
tonial injection of a mixture of ketamine (25 mg/kg) and medeto-
midine (0.2 mg/kg). The rats were injected into the tail vein with
28  11 MBq of 11C-GR218231. After 45 min of tracer distribu-
tion, the animals were sacrificed by extirpation of the heart. The
relevant tissues were excised and weighed. Tracer uptake in the
tissues was measured using a -counter and expressed as standard-
ized uptake value (SUV), which was defined as:
SUV 
Tissue activity concentration MBqg  Body weight g
Injected dose MBq .
Values were statistically analyzed using the 1-way ANOVA pro-
cedure followed by a Bonferroni multiple comparisons post hoc
test. Differences between groups were considered statistically sig-
nificant at P  0.01.
In the blocking experiments, the specific binding sites were
saturated by injection of 0.2 mg/kg or 2.5 mg/kg unlabeled
GR218231 into the tail vein 5 min before administration of the
tracer.
In modulation experiments, the P-glycoprotein pump was in-
hibited by injection of 50 mg/kg cyclosporine A into the tail vein
30 min before tracer injection.
The cyclosporine A dose-escalation studies were performed
several months after the other experiments on a different batch of
Wistar rats. In these studies, P-glycoprotein was modulated with 0,
10, 20, 30, 40 and 60 mg/kg cyclosporine A.
All animal studies were performed in compliance with the
national law on animal experiments. The protocols were approved
by the Animal Ethics Committee of the Groningen University.
Phosphor Storage Imaging
After 45 min of 11C-GR218231 distribution, isolated rat brains
were frozen in liquid nitrogen and stored on dry ice. The frozen
brain samples were cut into 80-m-thick slices, using a microtome
at 6°C. Brain slices were placed on slides and covered with a
multipurpose Cyclone Storage Phosphor Screen (Packard Instru-
ments). After exposure for 24 h, the phosphor screens were
scanned using a Cyclone imaging system (Packard Instruments).
RESULTS
Chemistry
The labeling precursor (compound 6) and a reference
sample of GR218231 were prepared as outlined in Figure 1.
First, 6-bromo-2-tetralone (compound 1) was converted into
compound 2 via a reductive alkylation with di-n-pro-
pylamine. Although reductive alkylations of ketones with
secondary amines can be difficult due to steric hindrance
(16), compound 2 could be produced in this manner in a
yield of 38%. Next, compound 2 was lithiated via a metallo-
dehalogenation reaction with n-butyllithium. The organo-
lithium intermediate was carbonylated in situ with DMF and
the resulting aldehyde was reduced with NaBH4. This 3-step
procedure gave compound 3 in 53% yield. Alcohol function
in compound 3 was converted into a chloride atom by
reaction with thionyl chloride. The crude chloride was re-
acted with either 4-mercaptophenol or 4-mercaptoanisol in
the presence of K2CO3 and Kryptofix 2.2.2. as a phase-
transfer catalyst. This 2-step reaction produced compounds
4 and 5 in 71% and 72% yield, respectively. 4-Mercapto-
phenol contains a hydroxyl and a thiol group that, in theory,
can act as the nucleophile in this substitution reaction.
Formation of the S-substituted product in the reaction with
4-mercaptophenol was confirmed by the 1H NMR chemical
shifts of the methylene group adjacent to the sulfur atom,
which was almost identical to the signal of the correspond-
ing protons in compound 5 ( 3.92 vs. 3.94). Under the
reaction conditions applied, no evidence for the formation
of the O-substituted product could be observed in the 1H
NMR spectrum of crude compound 4. Finally, compounds 4
and 5 were oxidized with m-chloroperbenzoic acid. When
this reaction was performed on the free amine of com-
pounds 4 or 5, oxidation predominantly occurred at the
nitrogen atom, yielding unidentified oxidation products,
which probably were N-oxides, hydroxylamines, and ni-
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troso compounds. This obstacle, however, could easily be
overcome by protonation of the amine group with HCl
before the oxidation reaction. The oxidation of the ammo-
nium salts of compounds 4 and 5 resulted in the formation
of the labeling precursor (compound 6) and reference com-
pound GR218231 in 43% and 50% yield, respectively.
Radiochemistry
The labeling of 11C-GR218231 was accomplished by
alkylation of compound 6 with 11C-methyl triflate, as de-
picted in Figure 2. After the phenol group of compound 6
was deprotonated with NaOH, 11C-methyl triflate was bub-
bled through the precursor solution, the solvent was evap-
orated, and the product was purified by reversed-phase
HPLC. For in vivo studies, the product was formulated in
10% ethanol in saline using a C18 solid-phase-extraction
cartridge. The entire labeling, purification, and formulation
procedure required approximately 40 min from the end of
bombardment. 11C-GR218231 was prepared with a specific
activity of 15  10 GBq/mol (at the end of synthesis) in
53%  8% decay-corrected radiochemical yield (n  18,
based on 11C-methyl triflate). Analytic HPLC showed that
the labeled product had a radiochemical purity of 99%.
Biodistribution
The resolution of our clinical PET camera does not allow
the discrimination of the relevant organs and individual
brain regions. Therefore, 11C-GR218231 was further eval-
uated in biodistribution studies instead of PET studies. A
45-min tracer distribution interval was chosen for the bio-
distribution studies. This time point should offer sufficient
distribution time to allow clearance of unbound tracer, while
maintaining reliable counting statistics of the short-lived
radionuclide in the small organs and brain areas of the rat.
Table 1 presents the distribution of 11C-GR218231 in vari-
ous peripheral tissues and brain regions at 45 min after
intravenous injection of the tracer, as determined by ex vivo
-counting. Highest tracer uptake was observed in stomach,
pancreas, kidney, and submandibular gland. The uptake of
11C-GR218231 in the brain was low and homogeneously
distributed, as the SUV in all brain areas ranged from 0.19
to 0.23. To determine whether the tracer uptake was due to
specific binding to the receptor, the receptor was saturated
with unlabeled drug by treating the animals with 0.2 or 2.5
mg/kg GR218231 5 min before administration of the tracer.
Pretreatment of the animals with 0.2 mg/kg unlabeled
GR218231 did not result in any significant reduction in
tracer uptake in any peripheral tissue or brain area (P 
1.0). Increasing the dose of unlabeled GR218231 to 2.5
mg/kg did not significantly affect the peripheral or cerebral
tracer uptake either (P 1.0 vs. controls and P 1.0 vs. the
0.2 mg/kg group; data not shown) and, thus, specific bind-
ing could not be demonstrated.
Modulation of P-Glycoprotein
To test whether the low cerebral uptake of 11C-GR218231
was due to the fact that the tracer is a substrate of the
P-glycoprotein pump, the effect of inhibition of the efflux
pump on the uptake of 11C-GR218231 was investigated. For
this purpose, Wistar rats were treated with the P-glycopro-
tein modulator, cyclosporine A (50 mg/kg), 30 min before
injection of the tracer. As shown in Table 1, modulation of
P-glycoprotein with cyclosporine A caused a tremendous
increase in cerebral uptake of 11C-GR218231 in all brain
areas (P  0.001). In the whole brain, overall tracer uptake
increased by 12-fold, whereas regional increases as high as
14-fold were observed. After modulation of the P-glyco-
protein pump, highest tracer uptake was found in striatum
and neocortex. The differences in tracer uptake between
brain areas, however, were not statistically significant (P 
0.08). In peripheral organs, tracer uptake was significantly
enhanced in spleen (80%, P  0.001), kidney (57%,
P  0.001), and heart (38%, P  0.005) after treatment
with cyclosporine A.
Phosphor Storage Imaging
Representative phosphor storage images of the 11C-
GR218231 uptake in the brain of control rats and in the
brain of rats that were treated with cyclosporine A are
depicted in Figure 3. This figure clearly demonstrates the
large increase in cerebral tracer uptake after modulation of
P-glycoprotein. Both in control rats and in P-glycoprotein–
modulated rats, the tracer is homogeneously distributed in
the brain.
Dose-Escalation Studies
As is depicted in Figure 4A, uptake of 11C-GR218231 in
the brain showed a sigmoidal relation with cyclosporine A
dosage. The cyclosporine A dosage at which 50% of the
maximum P-glycoprotein modulation was achieved (ED50)
was 23.3  0.6 mg/kg for the total brain. Only small
differences in the effect of cyclosporine A dosage on the
magnitude of 11C-GR218231 uptake were observed between
individual brain regions (Fig. 4B). The ED50 showed little
variation between brain regions and ranged from 21.7  0.1
mg/kg for striatum to 26.4  3.4 mg/kg for the olfactory
bulbs (Table 1). In peripheral organs, sigmoidal relations
between tracer uptake and modulator dosage were observed
only in pancreas and in spleen (Fig. 4C), indicating that
tracer uptake is influenced by P-glycoprotein in these or-
gans. In spleen, tracer uptake increased with increasing
cyclosporine A dosage (ED50, 38.4  2.4 mg/kg). Remark-
ably, 11C-GR218231 uptake decreased with increasing mod-
FIGURE 2. Radiolabeling of 11C-GR218231 via methylation of
desmethyl precursor with 11C-methyl triflate.
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ulator dosage in pancreas (ED50, 36.0  4.4 mg/kg). Tracer
uptake in heart (P  0.4) and kidney (P  0.1) could not be
correlated with modulator dosage by a sigmoidal fit.
DISCUSSION
In an attempt to develop an imaging method for the
dopamine D3 receptor using PET, we labeled the selective
dopamine D3 antagonist GR218231 with 11C. 11C-
GR218231 was reproducibly synthesized in good radio-
chemical yields that were sufficient for preclinical and clin-
ical studies. Biodistribution studies of 11C-GR218231 in rats
showed that the tracer uptake was homogeneously distrib-
uted throughout the central nervous system. The tracer
uptake did not correspond to the distribution of the dopa-
mine D3 receptor, which is heterogeneously distributed in
the brain, with highest concentrations in the islands of
Calleja, nucleus accumbens, ventral pallidum, substantia
nigra, and lobes 9 and 10 of the cerebellum (17), which
should have led to elevated uptake in the striatum, mesen-
cephalon, and caudal cerebellum. Tracer uptake could not
be blocked by pretreatment with 0.2 mg/kg unlabeled
GR218231. To ensure that the dopamine D3 receptors were
completely saturated with unlabeled GR218231, the block-
ing experiments were repeated using a 2.5 mg/kg dose of the
antagonist, but even at this high dose of blocker specific
binding could not be demonstrated. Similar results were
obtained by Sovago et al., who investigated the ligand
11C-RGH-1756 for imaging the dopamine D3 receptors in
monkey brain (18). Despite promising binding characteris-
tics of 11C-RGH-1756 in vitro, the ligand showed a homo-
geneous distribution with low levels of specific binding in
vivo. As a possible explanation, the authors suggested that
the dopamine D3 receptors could have been occupied by
endogenous dopamine, thus preventing binding of the ra-
dioligand. An alternative explanation could be the low
abundance of the dopamine D3 receptor, which leads to low
levels of specific binding that could have been obscured by
the nonspecific binding.
TABLE 1
Distribution of 11C-GR218231 in Various Peripheral Organs and Brain Regions 45 Minutes After








Bone 0.52  0.06 0.52  0.05 0.62  0.09
Colon 1.28  0.20 0.97  0.23 1.16  0.13
Duodenum 1.96  0.33 1.77  0.36 2.55  0.33
Fat 0.86  0.22 0.68  0.23 0.46  0.12
Heart 0.81  0.06 0.67  0.08 1.12  0.15† NS‡
Ileum 1.93  0.61 1.48  0.48 2.17  0.30
Kidney 3.07  0.42 2.55  0.36 4.81  0.81† NS‡
Liver 1.75  0.18 1.61  0.38 2.20  0.47
Lung 1.70  0.22 1.61  0.29 1.68  0.30
Muscle 0.57  0.06 0.58  0.05 0.70  0.13
Pancreas 4.24  0.72 3.14  1.39 2.29  0.68 36.0  4.4
Plasma 0.94  0.21 0.83  0.19 1.14  0.13
Red blood cells 0.32  0.04 0.31  0.03 0.42  0.04
Spleen 1.61  0.16 1.20  0.17 2.91  0.62† 38.4  2.4
Stomach 4.31  1.66 2.41  1.88 1.36  0.62
Submandibular gland 2.85  0.66 2.27  0.53 2.07  0.73
Trachea 0.96  0.09 0.86  0.11 0.91  0.09
Brain
Cerebellum, caudal 0.19  0.04 0.18  0.02 2.11  0.35† 24.5  1.7
Cerebellum, rostral 0.19  0.04 0.19  0.01 2.16  0.38† 24.8  1.9
Colliculi/geniculate 0.23  0.11 0.21  0.05 2.48  0.42† 23.4  1.8
Diencephalon 0.23  0.04 0.22  0.02 2.55  0.41† 23.6  0.8
Medulla oblongata 0.21  0.06 0.20  0.02 2.37  0.43† 22.1  2.6
Mesencephalon 0.19  0.05 0.19  0.01 2.49  0.40† 22.6  1.1
Olfactory bulbs 0.23  0.06 0.24  0.02 2.19  0.40† 26.4  3.4
Neocortex 0.21  0.05 0.22  0.01 2.85  0.56† 23.0  1.4
Pons 0.20  0.06 0.21  0.01 2.23  0.33† 23.1  2.0
Striatum 0.20  0.04 0.20  0.01 2.83  0.52† 21.7  0.1
*Cyclosporine A concentration at which 50% of maximum increase/decrease in tracer uptake is achieved.
†Significantly different from controls, as determined by 1-way ANOVA procedure followed by a Bonferroni multiple comparisons post hoc
test (P  0.01).
‡NS  not significant. Data could not be described by a sigmoidal curve.
Tissue uptake is expressed as SUV  SD.
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The most remarkable observation in this study was the
low cerebral uptake of 11C-GR218231 in control rats, which
was much lower than expected on basis of the lipophilicity
of the tracer (logD  2.2 (7)) (2). These results appear to
contradict pharmacologic studies that show that GR218231
can enter the brain of rats and bind to the dopamine D3
receptor, resulting in GR218231-mediated attenuation of
the dopaminergic behaviors induced by the preferential do-
pamine D3 receptor agonists 7-OH-DPAT and PD128,907
(6,8). Apparently, GR218231 shows sufficient brain uptake
at pharmacologic dosing but not at the tracer dosing that
was used in this study.
A possible explanation for the low uptake of 11C-
GR218231 in the rat brain at tracer dosing could be that the
tracer is extruded from the brain by an efflux pump in the
blood–brain barrier. The pharmacologic effect of
GR218231 that was observed at a high dosing could then be
due to saturation of the efflux pump, resulting in incomplete
removal of drug from the brain. We hypothesized that
P-glycoprotein could be the efflux pump that was responsi-
ble for the low brain uptake of 11C-GR218231. P-glycopro-
tein is abundant in the blood–brain barrier, where it can
extrude a variety of structurally unrelated drugs from the
brain.
To test our hypothesis, the influence of P-glycoprotein on
cerebral tracer uptake was investigated. P-glycoprotein
modulation induced a 12-fold increase in the brain uptake of
11C-GR218231, proving that GR218231 is a substrate of the
P-glycoprotein pump and that the low cerebral tracer uptake
in control animals was indeed caused by the efflux activity
of this pump. Although modulation of the P-glycoprotein
pump dramatically enhanced brain uptake of 11C-
GR218231, it did not result in any specific binding (data not
shown).
To further evaluate the feasibility of 11C-GR218231 as a
PET tracer for imaging of P-glycoprotein functionality, the
sensitivity of tracer uptake for cyclosporine A dosage was
investigated. Cerebral 11C-GR218231 uptake showed a sig-
moidal correlation with the dosage of cyclosporine A, indi-
cating that P-glycoprotein responsible for the efflux of the
tracer from the brain and that P-glycoprotein–mediated
FIGURE 3. Phosphor images of 11C-GR218231 binding in
coronal 80-m-thick brain slices of 50 mg/kg cyclosporine
A–treated (A) and control (B) rats. Each row depicts slices at
different Bregma levels (1.0, 4.8, and 12.8) and the corre-
sponding template (C).
FIGURE 4. Uptake of 11C-GR218231 in total brain (A), selected brain regions (B), and pancreas and spleen (C) for various dosages
of cyclosporine A. Tracer uptake is expressed as the mean SUV  SE. Plots of all tissues were fitted by a sigmoidal curve that is
described by the mathematic expression: y  y0 
axb
cb xb
(total brain: r2  0.87, P  0.0001; medulla oblongata: r2  0.88, P
 0.0001; mesencephalon: r2  0.89, P  0.0001; cerebellum: r2  0.85, P  0.0001; spleen: r2  0.53, P  0.006), except for the
fitted curve for pancreas, which is described by the equation: y  a 
b a
1 x/cd (r
2  0.55, P  0.005).
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transport is saturable. The ED50 of cyclosporine A for mod-
ulation of 11C-GR218231 uptake in the rat brain was 23.3 
0.6 mg/kg and varied little between individual brain regions.
This could imply that P-glycoprotein is rather homoge-
neously distributed throughout the blood–brain barrier. The
results of 11C-GR218231 are in agreement with previous
animal experiments with the P-glycoprotein tracers 11C-
verapamil and 11C-carvedilol, in which similar ED50 values
were observed (19,20).
Modulation of P-glycoprotein with cyclosporine A
caused a significant increase in tracer uptake not only in the
brain but also in the spleen, kidney, and heart. In contrast,
P-glycoprotein modulation resulted in a significant decrease
in 11C-GR218231 uptake in the pancreas. A sigmoidal re-
lationship between 11C-GR218231 uptake and cyclosporine
A dosage was observed for the spleen and pancreas. Low
levels of P-glycoprotein messenger RNA have been de-
tected in these organs (21). Splenic P-glycoprotein suppos-
edly is involved in the protection of the spleen by extrusion
of toxic unconjugated bilirubin, which is formed during
hemolysis (22). Thus, cyclosporine A–induced inhibition of
P-glycoprotein could explain the increase in tracer uptake in
the spleen in a similar manner as was described for the
brain. In the pancreas, P-glycoprotein is located on the
apical surface of small pancreatic ductules, where it is
responsible for the excretion physiologic metabolites and
chemotherapeutic drugs into the pancreatic duct (23). When
secretion of the tracer from the small pancreatic tubules into
the intestines is relatively slow, 11C-GR218231 will accu-
mulate in the pancreatic duct, resulting in the high pancre-
atic uptake that was observed in control animals. Inhibition
of P-glycoprotein would prevent the accumulation of the
tracer in the pancreatic duct, causing an overall reduction in
tracer uptake in the pancreas. This would explain the sig-
moidal decrease in pancreatic tracer uptake in response to
P-glycoprotein modulation.
In contrast to brain, spleen, and pancreas, tracer uptake in
kidney and heart did not have a sigmoidal relationship with
the cyclosporine A dosage. Tracer uptake in kidney and
heart showed a slight decrease after modulation with 10 and
20 mg/kg cyclosporin A but showed an increase at higher
dosages. The effect of cyclosporine A pretreatment on tracer
uptake in kidney and heart could be due to cyclosporine
A–mediated variations in the plasma clearance (24). In fact,
average plasma levels of the tracer showed a similar pattern
in the response to cyclosporine A dosage as tracer uptake in
kidney and heart. Therefore, 11C-GR218231 uptake does not
seem to be significantly affected by P-glycoprotein transport
in these organs but predominantly by cyclosporine A–me-
diated effects on plasma clearance.
Taken together, these results show that 11C-GR218231 is
not a suitable PET tracer for dopamine D3 receptor imaging,
but it could be useful for imaging of P-glycoprotein in the
blood–brain barrier. A PET method for imaging of P-
glycoprotein functionality could provide a useful tool to
improve pharmacotherapeutic treatment with drugs that ex-
ert their activity in the central nervous system. Information
about the functionality of the P-glycoprotein pump could be
of major clinical and pharmaceutical importance, since ther-
apeutic drugs can become ineffective when drug levels in
the brain are reduced by the efflux activity of the P-glyco-
protein. Modulation of the P-glycoprotein pump may re-
store the efficacy of these drugs. P-glycoprotein can also be
involved in undesired drug–drug interactions when multiple
drugs that are substrates of the efflux pump are administered
simultaneously. Competition for the efflux pump results in
increased concentrations of the drugs in the brain, which can
lead to unexpected neurotoxic side effects. Identification of
drugs that are substrates of P-glycoprotein could prevent
these harmful drug–drug interactions.
Imaging of P-glycoprotein could also be applied to de-
termine the status of the efflux pump—for example, in
neurodegenarative diseases. Recently, Kortekaas et al. used
the P-glycoprotein substrate 11C-verapamil and PET to
show that P-glycoprotein activity in the affected midbrain of
patients with Parkinson’s disease is reduced compared with
that of healthy volunteers, suggesting a causative relation
between P-glycoprotein dysfunction and Parkinson’s dis-
ease (5).
CONCLUSION
The dopamine D3 receptor antagonist GR218231 was
reliably labeled with 11C in good radiochemical yield. 11C-
GR218231 does not appear to be suited as a PET tracer for
dopamine D3 receptor imaging, as uptake of the tracer in the
brain was low, did not correspond to the regional distribu-
tion of the dopamine D3 receptor, and appeared to be non-
specific. 11C-GR218231 proved to be an excellent substrate
of the P-glycoprotein efflux pump in the blood–brain bar-
rier, resulting in rapid extrusion of the tracer from the brain.
Modulation of the P-glycoprotein pump with cyclosporine
A induced an enormous increase in the cerebral uptake of
11C-GR218231. These findings indicate that 11C-GR218231
might be useful as a PET tracer for the visualization and
quantification of P-glycoprotein function in the blood–brain
barrier. An in vivo imaging technique to monitor the P-
glycoprotein function in the blood–brain barrier could aid
the development of new drugs and novel strategies to de-
liver drugs to the brain and might be able to identify
undesirable drug–drug interactions (3).
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